The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Multiple Myeloma Drugs Market Research Report 2024
Synopsis
Multiple myeloma drugs fall into various drug classes, including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), alkylating agents, corticosteriods, histone deactylase inhibitors (HDACs), bisphophonates, and monoclonal antibodies (MAbs).
The global Multiple Myeloma Drugs market was valued at US$ 874 million in 2023 and is anticipated to reach US$ 1271.1 million by 2030, witnessing a CAGR of 6.2% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Multiple Myeloma Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Multiple Myeloma Drugs.
Report Scope
The Multiple Myeloma Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Multiple Myeloma Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Multiple Myeloma Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen
Johnson & Johnson
Celgene
Takeda Pharmaceutical
Novartis
Daiichi Sankyo
Merck
AB Science
Teva
PharmaMar
Segment by Type
Chemotherapy
Corticosteroids
Immunomodulators
Monoclonal Antibodies
Histone Deacetylase (HDAC) Inhibitors
Proteasome Inhibitors
Others
Segment by Application
Men
Women
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Multiple Myeloma Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Multiple Myeloma Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Multiple myeloma drugs fall into various drug classes, including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), alkylating agents, corticosteriods, histone deactylase inhibitors (HDACs), bisphophonates, and monoclonal antibodies (MAbs).
The global Multiple Myeloma Drugs market was valued at US$ 874 million in 2023 and is anticipated to reach US$ 1271.1 million by 2030, witnessing a CAGR of 6.2% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Multiple Myeloma Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Multiple Myeloma Drugs.
Report Scope
The Multiple Myeloma Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Multiple Myeloma Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Multiple Myeloma Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen
Johnson & Johnson
Celgene
Takeda Pharmaceutical
Novartis
Daiichi Sankyo
Merck
AB Science
Teva
PharmaMar
Segment by Type
Chemotherapy
Corticosteroids
Immunomodulators
Monoclonal Antibodies
Histone Deacetylase (HDAC) Inhibitors
Proteasome Inhibitors
Others
Segment by Application
Men
Women
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Multiple Myeloma Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Multiple Myeloma Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Multiple Myeloma Drugs Market Overview
1.1 Product Overview and Scope of Multiple Myeloma Drugs
1.2 Multiple Myeloma Drugs Segment by Type
1.2.1 Global Multiple Myeloma Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Chemotherapy
1.2.3 Corticosteroids
1.2.4 Immunomodulators
1.2.5 Monoclonal Antibodies
1.2.6 Histone Deacetylase (HDAC) Inhibitors
1.2.7 Proteasome Inhibitors
1.2.8 Others
1.3 Multiple Myeloma Drugs Segment by Application
1.3.1 Global Multiple Myeloma Drugs Market Value by Application: (2024-2030)
1.3.2 Men
1.3.3 Women
1.4 Global Multiple Myeloma Drugs Market Size Estimates and Forecasts
1.4.1 Global Multiple Myeloma Drugs Revenue 2019-2030
1.4.2 Global Multiple Myeloma Drugs Sales 2019-2030
1.4.3 Global Multiple Myeloma Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Multiple Myeloma Drugs Market Competition by Manufacturers
2.1 Global Multiple Myeloma Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Multiple Myeloma Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Multiple Myeloma Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Multiple Myeloma Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Multiple Myeloma Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Multiple Myeloma Drugs, Product Type & Application
2.7 Multiple Myeloma Drugs Market Competitive Situation and Trends
2.7.1 Multiple Myeloma Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Multiple Myeloma Drugs Players Market Share by Revenue
2.7.3 Global Multiple Myeloma Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Multiple Myeloma Drugs Retrospective Market Scenario by Region
3.1 Global Multiple Myeloma Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Multiple Myeloma Drugs Global Multiple Myeloma Drugs Sales by Region: 2019-2030
3.2.1 Global Multiple Myeloma Drugs Sales by Region: 2019-2024
3.2.2 Global Multiple Myeloma Drugs Sales by Region: 2025-2030
3.3 Global Multiple Myeloma Drugs Global Multiple Myeloma Drugs Revenue by Region: 2019-2030
3.3.1 Global Multiple Myeloma Drugs Revenue by Region: 2019-2024
3.3.2 Global Multiple Myeloma Drugs Revenue by Region: 2025-2030
3.4 North America Multiple Myeloma Drugs Market Facts & Figures by Country
3.4.1 North America Multiple Myeloma Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Multiple Myeloma Drugs Sales by Country (2019-2030)
3.4.3 North America Multiple Myeloma Drugs Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Multiple Myeloma Drugs Market Facts & Figures by Country
3.5.1 Europe Multiple Myeloma Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Multiple Myeloma Drugs Sales by Country (2019-2030)
3.5.3 Europe Multiple Myeloma Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Multiple Myeloma Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Multiple Myeloma Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Multiple Myeloma Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Multiple Myeloma Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Multiple Myeloma Drugs Market Facts & Figures by Country
3.7.1 Latin America Multiple Myeloma Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Multiple Myeloma Drugs Sales by Country (2019-2030)
3.7.3 Latin America Multiple Myeloma Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Multiple Myeloma Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Multiple Myeloma Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Multiple Myeloma Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Multiple Myeloma Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Multiple Myeloma Drugs Sales by Type (2019-2030)
4.1.1 Global Multiple Myeloma Drugs Sales by Type (2019-2024)
4.1.2 Global Multiple Myeloma Drugs Sales by Type (2025-2030)
4.1.3 Global Multiple Myeloma Drugs Sales Market Share by Type (2019-2030)
4.2 Global Multiple Myeloma Drugs Revenue by Type (2019-2030)
4.2.1 Global Multiple Myeloma Drugs Revenue by Type (2019-2024)
4.2.2 Global Multiple Myeloma Drugs Revenue by Type (2025-2030)
4.2.3 Global Multiple Myeloma Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Multiple Myeloma Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Multiple Myeloma Drugs Sales by Application (2019-2030)
5.1.1 Global Multiple Myeloma Drugs Sales by Application (2019-2024)
5.1.2 Global Multiple Myeloma Drugs Sales by Application (2025-2030)
5.1.3 Global Multiple Myeloma Drugs Sales Market Share by Application (2019-2030)
5.2 Global Multiple Myeloma Drugs Revenue by Application (2019-2030)
5.2.1 Global Multiple Myeloma Drugs Revenue by Application (2019-2024)
5.2.2 Global Multiple Myeloma Drugs Revenue by Application (2025-2030)
5.2.3 Global Multiple Myeloma Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Multiple Myeloma Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Amgen
6.1.1 Amgen Corporation Information
6.1.2 Amgen Description and Business Overview
6.1.3 Amgen Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Amgen Multiple Myeloma Drugs Product Portfolio
6.1.5 Amgen Recent Developments/Updates
6.2 Johnson & Johnson
6.2.1 Johnson & Johnson Corporation Information
6.2.2 Johnson & Johnson Description and Business Overview
6.2.3 Johnson & Johnson Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Johnson & Johnson Multiple Myeloma Drugs Product Portfolio
6.2.5 Johnson & Johnson Recent Developments/Updates
6.3 Celgene
6.3.1 Celgene Corporation Information
6.3.2 Celgene Description and Business Overview
6.3.3 Celgene Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Celgene Multiple Myeloma Drugs Product Portfolio
6.3.5 Celgene Recent Developments/Updates
6.4 Takeda Pharmaceutical
6.4.1 Takeda Pharmaceutical Corporation Information
6.4.2 Takeda Pharmaceutical Description and Business Overview
6.4.3 Takeda Pharmaceutical Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Takeda Pharmaceutical Multiple Myeloma Drugs Product Portfolio
6.4.5 Takeda Pharmaceutical Recent Developments/Updates
6.5 Novartis
6.5.1 Novartis Corporation Information
6.5.2 Novartis Description and Business Overview
6.5.3 Novartis Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Novartis Multiple Myeloma Drugs Product Portfolio
6.5.5 Novartis Recent Developments/Updates
6.6 Daiichi Sankyo
6.6.1 Daiichi Sankyo Corporation Information
6.6.2 Daiichi Sankyo Description and Business Overview
6.6.3 Daiichi Sankyo Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Daiichi Sankyo Multiple Myeloma Drugs Product Portfolio
6.6.5 Daiichi Sankyo Recent Developments/Updates
6.7 Merck
6.6.1 Merck Corporation Information
6.6.2 Merck Description and Business Overview
6.6.3 Merck Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Merck Multiple Myeloma Drugs Product Portfolio
6.7.5 Merck Recent Developments/Updates
6.8 AB Science
6.8.1 AB Science Corporation Information
6.8.2 AB Science Description and Business Overview
6.8.3 AB Science Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 AB Science Multiple Myeloma Drugs Product Portfolio
6.8.5 AB Science Recent Developments/Updates
6.9 Teva
6.9.1 Teva Corporation Information
6.9.2 Teva Description and Business Overview
6.9.3 Teva Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Teva Multiple Myeloma Drugs Product Portfolio
6.9.5 Teva Recent Developments/Updates
6.10 PharmaMar
6.10.1 PharmaMar Corporation Information
6.10.2 PharmaMar Description and Business Overview
6.10.3 PharmaMar Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 PharmaMar Multiple Myeloma Drugs Product Portfolio
6.10.5 PharmaMar Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Multiple Myeloma Drugs Industry Chain Analysis
7.2 Multiple Myeloma Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Multiple Myeloma Drugs Production Mode & Process
7.4 Multiple Myeloma Drugs Sales and Marketing
7.4.1 Multiple Myeloma Drugs Sales Channels
7.4.2 Multiple Myeloma Drugs Distributors
7.5 Multiple Myeloma Drugs Customers
8 Multiple Myeloma Drugs Market Dynamics
8.1 Multiple Myeloma Drugs Industry Trends
8.2 Multiple Myeloma Drugs Market Drivers
8.3 Multiple Myeloma Drugs Market Challenges
8.4 Multiple Myeloma Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
